Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

We have reported that osteoclast differentiation factor (ODF) expressed on the plasma membrane of osteoblasts/ stromal cells is a ligand for osteoclastogenesis inhibitory factor (OCIF). A genetically engineered soluble form of ODF (sODF) induced osteoclast-like multinucleated cells (OCLs) in the presence of M-CSF in mouse spleen cell cultures. Osteoblasts/stromal cells were not required in this process. To elucidate the mechanism of human osteoclastogenesis, human peripheral blood mononuclear cells (PBMCs) were cultured for 7 days with sODF and human M-CSF in the presence or absence of dexamethasone. Treatment of human PBMCs with sODF together with M-CSF induced OCLs, which expressed tartrate-resistant acid phosphatase and vitronectin receptors, produced cAMP in response to calcitonin, and formed resorption pits on dentine slices. OCLs were also formed from the adherent cell population of human PBMCs. Dexamethasone was required for human OCL formation in culture of whole PBMCs but not in culture of the adherent cell population. OCL formation was strongly inhibited by OCIF simultaneously added. These results clearly indicate that like in mouse osteoclastogenesis, ODF is a critical factor for human osteoclastogenesis. The present study also indicates that OCIF acts as a naturally occurring decoy receptor for ODF in inhibiting signal transduction in human osteoclast formation.

[1]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[2]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  M. Horton,et al.  Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. , 1985, Cancer research.

[4]  M. Noble,et al.  Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[7]  N. Athanasou,et al.  Cellular biology of bone-resorbing cells. , 1996, The Journal of bone and joint surgery. American volume.

[8]  S. Niida,et al.  Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor , 1991, The Journal of experimental medicine.

[9]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[10]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[11]  M. Cecchini,et al.  Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. , 1990, Endocrinology.

[12]  A. Flanagan,et al.  Inhibition of bone resorption by 17β‐estradiol in human bone marrow cultures , 1998, Journal of cellular physiology.

[13]  B. Torok-Storb,et al.  Normal Human Peripheral Blood Mononuclear Cells Mobilized With Granulocyte Colony-Stimulating Factor Have Increased Osteoclastogenic Potential Compared To Nonmobilized Blood , 1996 .

[14]  Roodman Gd Advances in bone biology: the osteoclast. , 1996, Endocrine reviews.

[15]  A. Flanagan,et al.  Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. , 1996, Blood.

[16]  J O McGee,et al.  The human osteoclast precursor circulates in the monocyte fraction. , 1996, Endocrinology.

[17]  M. Goto,et al.  Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor* , 1998, The Journal of Biological Chemistry.

[18]  M. Horton,et al.  An assessment of the ability of human bone marrow cultures to generate osteoclasts. , 1992, International journal of experimental pathology.

[19]  J. Haug,et al.  Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[21]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[22]  John P. Bilezikian,et al.  Principles of Bone Biology , 1996 .

[23]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[24]  E. Jimi,et al.  Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. , 1997, Methods in enzymology.

[25]  T. Martin,et al.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Obinata,et al.  Establishment and characterization of bone marrow stromal cell lines that support osteoclastogenesis. , 1995, Endocrinology.